Latanoprost for the Treatment of Menière's Disease

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Synphora AB Identifier:
First received: October 17, 2013
Last updated: March 22, 2016
Last verified: March 2016
The purpose of the study is to evaluate the dose regimen, efficacy and safety of latanoprost for the treatment of Menière's disease.

Condition Intervention Phase
Menière's Disease
Drug: Latanoprost
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease

Resource links provided by NLM:

Further study details as provided by Synphora AB:

Primary Outcome Measures:
  • Change in speech discrimination score in noise from Baseline [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in speech discrimination score in noise from Baseline [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change in pure tone audiometry from Baseline [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change in THI-25 (Tinnitus Handicap Inventory) score from Baseline [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change in hearing (Likert scale), tinnitus (Likert scale) and vertigo (Likert scale) from run-in period [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Change in proportion of days with vertigo attacks from run-in period [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Comparison of number of drop attacks in each treatment arm [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Evaluation of adverse events and vital signs as measure of safety and tolerability [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Enrollment: 100
Study Start Date: October 2013
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
One intratympanic injection of latanoprost (Day1)
Drug: Latanoprost
Placebo Comparator: Group 2
One intratympanic injection of placebo
Other: Placebo
Experimental: Group 3
Three intratympanic injections of latanoprost (Day 1, 2 and 3)
Drug: Latanoprost
Placebo Comparator: Group 4
Three intratympanic injections of placebo (Day 1, 2 and 3)
Other: Placebo


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age
  • Definitive unilateral Menière's disease (AAO-HNS 1995)
  • Disease stage II - III: PTA4 (Pure Tone Average) (0.5, 1.0, 2.0 and 3.0kHz) between 25dB and 70dB
  • Speech discrimination score in silence: No better than 85%
  • At least three vertigo attacks (lasting ≥ 20 minutes) during the last three months prior to inclusion
  • Tinnitus during the last three months prior to inclusion
  • Signed written informed consent

Exclusion Criteria:

  • Medical or psychiatric conditions which could jeopardize or would compromise the subject's ability to participate in the trial or decrease the likelihood of obtaining satisfactory data to achieve the objective of the trial, dementia, alcohol or substance abuse.
  • Bilateral Menière's disease
  • Chronic otitis media on the ear affected by Menière's disease
  • Subjects not fluent in Swedish language
  • Bronchial asthma
  • Previous intratympanic injection of gentamicin or surgical therapy
  • Previous intratympanic steroid therapy less than six months prior to inclusion
  • Known hypersensitivity to local anesthetics
  • Pregnant women
  • Nursing mothers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01973114

Falu Lasarett
Falun, Sweden
Sahlgrenska Universitetssjukhuset
Göteborg, Sweden
Blekinge Hospital
Karlskrona, Sweden
Centralsjukhuset i Karlstad
Karlstad, Sweden
Centralsjukhuset i Kristianstad
Kristianstad, Sweden
Linköping University Hospital
Linköping, Sweden
Sunderby Sjukhus
Luleå, Sweden
Lund University Hospital
Lund, Sweden
Karolinska Universitetssjukhuset
Stockholm, Sweden
Uppsala University Hospital
Uppsala, Sweden
Västmanlands Sjukhus i Västerås
Västerås, Sweden
University Hospital Örebro
Örebro, Sweden
Sponsors and Collaborators
Synphora AB
Principal Investigator: Mikael Karlberg, MD, PhD Lund University Hospital
  More Information

Responsible Party: Synphora AB Identifier: NCT01973114     History of Changes
Other Study ID Numbers: M 05 - 2013 
Study First Received: October 17, 2013
Last Updated: March 22, 2016
Health Authority: Sweden: Medical Products Agency

Keywords provided by Synphora AB:
Menière's disease
Hearing loss

Additional relevant MeSH terms:
Meniere Disease
Ear Diseases
Endolymphatic Hydrops
Labyrinth Diseases
Otorhinolaryngologic Diseases
Antihypertensive Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses processed this record on May 04, 2016